Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Read Our Latest Report on AXDX

Accelerate Diagnostics Price Performance

AXDX opened at $1.35 on Friday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $4.07. The stock has a 50-day moving average price of $1.56 and a 200-day moving average price of $1.54. The firm has a market cap of $33.81 million, a PE ratio of -0.47 and a beta of 0.59.

Insider Activity at Accelerate Diagnostics

In related news, Director John Patience acquired 200,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average cost of $1.57 per share, with a total value of $314,000.00. Following the completion of the acquisition, the director now directly owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 43.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Accelerate Diagnostics

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent reporting period. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Further Reading

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.